The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Subscribe To Our Newsletter & Stay Updated
